San Diego, CA, USA – November 30, 2015 –HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed a Memorandum of Understanding with the Korea Drug Development Fund (KDDF) to foster collaboration between KDDF and HUYA with the ultimate goal of advancing Korean development and commercialization of healthcare products for the global market.
HUYA Bioscience International Celebrates its 10th Anniversary
San Diego Biotech Firm Commemorates a Decade of Innovation
San Diego, CA, USA – November 16, 2015 –HUYA Bioscience International (HUYA) just celebrated its 10th anniversary of the company’s founding with a black tie gala event on November 13 at the U.S. Grant Hotel in San Diego. The company honored its 10 years of international pharmaceutical innovation and development with live entertainment and video greetings from colleagues and key opinion leaders in Japan and China.
HUYA Bioscience International and TechCode Gu’an Lifesciences Park Establish Strategic Collaboration
San Diego, CA, USA – November 9, 2015 –HUYA Bioscience International, the leader in accelerating the global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with TechCode Gu’an Life Sciences Park (referred to as TechCode Gu’an Park). The collaboration will focus on promoting the development of biomedical innovations from companies located in the park that could help meet the growing demand to fill global pharmaceutical pipelines.
HUYA Bioscience International Further Expands Executive Team
Appoints Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer
San Diego, CA, USA – September 15, 2015 –HUYA Bioscience International (HUYA) today announced the expansion of its Executive Team with the appointment of Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer.
HUYA Bioscience International Sponsors Japan Society of HTLV-1 Annual Meeting
San Diego, CA, USA – August 27, 2015 –HUYA Bioscience International (HUYA) today announced the sponsorship of the second annual meeting of the Japan Society of HTLV-1, held this week at the University of Tokyo Medical Science Institute Auditorium.
HUYA Bioscience International CEO, Mireille Gillings, Ph.D., Named As Gold Award Winner In 2015 American Business Awards
13th annual Stevie® Awards presented on June 22 in Chicago
San Diego, CA, USA – June 23, 2015 –HUYA Bioscience International CEO and Executive Chairman, Mireille Gillings, Ph.D., has been named a Gold Stevie® Award Winner in the ‘Woman of the Year, Health Products and Services & Pharmaceuticals’ category in The 2015 American Business Awards.
HUYA Bioscience International Wins Bronze Stevie® Award In 2015 Asia-Pacific Stevie Awards
Winners to be Celebrated at Gala Banquet on 5 June in Shanghai, China
San Diego, CA, USA & Shanghai, China – May 26, 2015 –HUYA Bioscience International has been named the winner of a bronze Stevie® Award in the Health Products & Services and Pharmaceuticals category in the second annual Asia-Pacific Stevie Awards.
HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan
Second cohort underway in non-Hodgkin’s lymphoma patients
San Diego, CA, USA – March 19, 2015 –HUYA Bioscience International (HUYA) has completed the first cohort in a Phase 1 clinical trial in Japan of its cancer drug HBI-8000, a novel oral histone deacetylase (HDAC) inhibitor. This follows acceptance by the Pharmaceutical and Medical Devices Agency (PMDA) of the company’s accelerated development strategy in Japan. Continue reading
HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
HUYA holds exclusive rights to chidamide as HBI-8000 ex-China
San Diego, CA, USA – January 12, 2015 –HUYA Bioscience International (HUYA) announced today that Shenzhen Chipscreen Biosciences (Chipscreen) has obtained marketing approval from the Chinese FDA for the world’s first oral HDAC inhibitor, chidamide, for the treatment of relapsed or refractory peripheral T-cell lymphoma. Chidamide (Epidaza®) is an orally bioavailable, benzamide-class small molecule, that selectively inhibits cancer-associated HDAC (histone deacetylase) enzymes. Chidamide has anti-tumor activity through various mechanisms of action, including epigenetic reprogramming and immunomodulation. HUYA has exclusive rights to chidamide (HBI-8000) worldwide, excluding China, and is developing HBI-8000 for the treatment of hematological and solid tumors. Continue reading
HUYA Bioscience International Is The First To Leverage Tripartite Cooperation
PMDA accepts accelerated development strategy for HBI-8000, a novel cancer drug
San Diego, CA, USA – January 8, 2015 –HUYA Bioscience International (HUYA) announced today that the Pharmaceutical and Medical Devices Agency (PMDA) has accepted its accelerated development strategy for the novel cancer drug HBI-8000. HUYA is developing HBI-8000 for the treatment of adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) in Japan. Continue reading